The pathophysiology of the peritoneal membrane

Journal of the American Society of Nephrology

Volumn 21, Issue 7, 2010, Pages 1077-1085

  Devuyst, Olivier ^a   Margetts, Peter J ^b   Topley, Nicholas ^c  

^a UCL   (Belgium)

^b MCMASTER UNIVERSITY   (Canada)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; NITROUS OXIDE; RAPAMYCIN; SOLUBLE INTERLEUKIN 6 RECEPTOR; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; UVOMORULIN;

ACUTE DISEASE; ANGIOGENESIS; CELL MIGRATION; ENDOTHELIUM; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSIS; HOST RESISTANCE; INFLAMMATION; LEUKOCYTE; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS EPIDERMIDIS; TISSUE REPAIR; TRANSGENIC MOUSE; ULTRAFILTRATION;

EID: 77954591980     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009070694     Document Type: Review

References (79)

1. Grassmann A, Gioberge S, Moeller S, Brown G: ESRD patients in 2004: Global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 20: 2587-2593, 2005
2. Margetts PJ, Churchill DN: Acquired ultrafiltration dysfunction in peritoneal dialysis patients. J Am Soc Nephrol 13: 2787-2794, 2002 (Pubitemid 35216050)
3. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT, Peritoneal Biopsy Study Group: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13: 470-479, 2002
4. Devuyst O, van Westrhenen R, Topley N: Long-term peritoneal dialysis patients. In: Nolph and Gokal's Textbook of Peritoneal Dialysis, 3rd Ed., edited by Khanna R, Krediet RT, New York, Springer, 2009, pp 757-780
5. Garosi G: Different aspects of peritoneal damage: Fibrosis and sclerosis. Contrib Nephrol 163: 45-53, 2009
6. Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME: Encapsulating peritoneal sclerosis: Clinical significance and implications. Nephron Clin Pract 111: c149-c54, 2009
7. Carlsson O, Nielsen S, Zakaria el-R, Rippe B: In vivo inhibition of transcellular water channels (aquaporin-1) during acute peritoneal dialysis in rats. Am J Physiol 271: H2254-H2262, 1996
8. Ferrier ML, Combet S, van Landschoot M, Stoenoiu MS, Cnops Y, Lameire N, Devuyst O: Inhibition of nitric oxide synthase reverses changes in peritoneal permeability in a rat model of acute peritonitis. Kidney Int 60: 2343-2350, 2001
9. De Vriese AS, Tilton RG, Stephan CC, Lameire NH: Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 12: 1734-1741, 2001 (Pubitemid 32674437)
10. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, Gauldie J: Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 13: 721-728, 2002 (Pubitemid 34183938)
11. Miyata T, Devuyst O, Kurokawa K: Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 61: 375-386, 2002
12. Topley N: Animal models in peritoneal dialysis: More questions than answers? Perit Dial Int 25: 33-34, 2005
13. Lameire N, Van Biesen W, Mortier S, De Vriese A: What did we learn from animal models in peritoneal dialysis? Contrib Nephrol 150: 70-76, 2006
14. Rao S, Verkman AS: Analysis of organ physiology in transgenic mice. Am J Physiol Cell Physiol 279: C1-C18, 2000
15. Ni J, Moulin P, Gianello P, Feron O, Balligand JL, Devuyst O: Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 14: 3205-3216, 2003
16. Ni J, Cnops Y, Debaix H, Boisdé I, Verbavatz JM, Devuyst O: Functional and molecular characterization of a peritoneal dialysis model in the C57BL/6J mouse. Kidney Int 67: 2021-2031, 2005
17. Goltoib L: Functional structure of the peritoneum as a dialysing membrane. In: Nolph and Gokal's Textbook of Peritoneal Dialysis, 3rd Ed., edited by Khanna R, Krediet RT, New York, Springer, 2009, pp 73-136
18. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegel W, Divino Filho JC, Vonesh E, van Bree M, EAPOS Group: Survival of functionally anuric patients on automated peritoneal dialysis: The European APD Outcome Study. J Am Soc Nephrol 14: 2948-2957, 2003
19. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG: Meta-analysis: Peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 17: 2591-2598, 2006
20. Rippe B, Stelin G, Haraldsson B: Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 40: 315-325, 1991
21. Rippe B, Venturoli D, Simonsen O, de Arteaga J: Fluid and electrolyte transport across the peritoneal membrane during CAPD according to the three-pore model. Perit Dial Int 24: 10-27, 2004 (Pubitemid 38886091)
22. Agre P: Aquaporin water channels (Nobel Lecture). Angew Chem Int Ed Engl 43: 4278-4290, 2004
23. Nielsen S, Smith BL, Christensen EI, Agre P: Distribution of the aquaporin CHIP in secretory and resorptive epithelia and capillary endothelia. Proc Natl Acad Sci U S A 90: 7275-7279, 1993 (Pubitemid 23222432)
24. Devuyst O, Nielsen S, Cosyns JP, Smith BL, Agre P, Goffin E: Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum. Am J Physiol 275: H234-H242, 1998
25. Yang B, Folkesson HG, Yang J, Matthay MA, Ma T, Verkman AS: Reduced osmotic water permeability of the peritoneal barrier in aquaporin-1 knockout mice. Am J Physiol 276: C76-C81, 1999 (Pubitemid 29063569)
26. Ni J, Verbavatz JM, Rippe A, Boisdé I, Moulin P, Rippe B, Verkman AS, Devuyst O: Aquaporin-1 plays an essential role in water permeability and ultrafiltration during peritoneal dialysis. Kidney Int 69: 1518-1525, 2006
27. Stoenoiu MS, Ni J, Verkaeren C, Debaix H, Jonas J-C, Lameire N, Verbavatz J-M, Devuyst O: Corticosteroids induce expression of aquaporin-1 and increase transcellular water transport in rat peritoneum. J Am Soc Nephrol 14: 555-565, 2003
28. Krediet RT, Zuyderhoudt FM, Boeschoten EW, Arisz L: Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest 17: 43-52, 1987 (Pubitemid 17020044)
29. Combet S, van Landschoot M, Moulin P, Piech A, Verbavatz JM, Goffin E, Balligand JL, Lameire N, Devuyst O: Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis. J Am Soc Nephrol 10: 2185-2196, 1999
30. Douma CE, de Waart DR, Struijk DG, Krediet RT: Are phospholipase A2 and nitric oxide involved in the alterations in peritoneal transport during CAPD peritonitis? J Lab Clin Med 132: 329-340, 1998
31. Ni J, Cnops Y, McLoughlin RM, Topley N, Devuyst O: Inhibition of nitric oxide synthase reverses permeability changes in a mouse model of acute peritonitis. Perit Dial Int 25: S11-S14, 2005
32. Combet S, Balligand JL, Lameire N, Goffin E, Devuyst O: A specific method for measurement of nitric oxide synthase enzymatic activity in peritoneal biopsies. Kidney Int 57: 332-338, 2000
33. Förstermann U, Kleinert H: Nitric oxide synthase: Expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 352: 351-364, 1995
34. Ni J, McLoughlin RM, Brodovitch A, Moulin P, Brouckaert P, Casadei B, Feron O, Topley N, Balligand JL, Devuyst O: Nitric oxide synthase isoforms play distinct roles during acute peritonitis. Nephrol Dial Transplant 25: 86-96, 2010
35. Bellingan GJ, Caldwell H, Howie SE, Darnsfield I, Haslett C: In vivo fate of the inflammatory macrophage during the resolution of inflammation. J Immunol 157: 2577-2585, 1996
36. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK: IL-6 is an anti-inflammatory cytokine required for controlling local and systemic acute inflammatory responses. J Clin Invest 101: 311-320, 1998
37. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM: The soluble interleukin-6 receptor: Mechanisms of production and implications in disease. FASEB J 15: 43-58, 2001
38. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705-714, 2001
39. McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, Williams AS, Williams JD, Rose-John S, Jones SA, Topley N: Interplay between IFN-γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 112: 598-607, 2003
40. McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, Ernst M, Topley N, Jones SA: IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 102: 9589-9594, 2005
41. Topley N, Jörres A, Luttmann W, Petersen MM, Lang MJ, Thierauch KH, Müller C, Coles GA, Davies M, Williams JD: Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1 beta and TNF alpha. Kidney Int 43: 226-233, 1993
42. Witowski J, Jörres A, Coles GA, Williams JD, Topley N: Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. Kidney Int 50: 1212-1223, 1996 (Pubitemid 26342812)
43. Nowell MA, Williams AS, Carty SA, Scheller J, Hayes AJ, Jones GW, Richards PJ, Slinn S, Ernst M, Jenkins BJ, Topley N, Rose-John S, Jones SA: Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 182: 613-622, 2009
44. Kato S, Yuzawa Y, Tsuboi N, Maruyama S, Morita Y, Matsuguchi T, Matsuo S: Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells: The role of toll-like receptor 4. J Am Soc Nephrol 15: 1289-1299, 2004
45. Raby AC, Le Bouder E, Colmont C, Davies J, Richards P, Coles B, George CH, Jones SA, Brennan P, Topley N, Labéta MO: Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol 183: 506-517, 2009
46. Yáñez-Mó M, Lara-Pezzi E, Selgas R, Ramírez-Huesca M, Domínguez-Jiménez C, Jiménez- Heffernan JA, Aguilera A, Sánchez-Tomero JA, Bajo MA, Alvarez V, Castro MA, del Peso G, Cirujeda A, Gamallo C, Sánchez-Madrid F, López-Cabrera M: Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 348: 403-413, 2003
47. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, West-Mays JA, Kelly MM: Transient overexpression of TGF-beta1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 16: 425-436, 2005
48. Aroeira LS, Aguilera A, Selgas R, Ramírez-Huesca M, Pérez-Lozano ML, Cirugeda A, Bajo MA, del Peso G, Sánchez-Tomero JA, Jiménez-Heffernan JA, López-Cabrera M: Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: Role of vascular endothelial growth factor. Am J Kidney Dis 46: 938-948, 2005
49. Del Peso G, Jiménez-Heffernan JA, Bajo MA, Aroeira LS, Aguilera A, Fernández-Perpén A, Cirugeda A, Castro MJ, de Gracia R, Sánchez-Villanueva R, Sánchez-Tomero JA, López-Cabrera M, Selgas R: Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int 108: S26-S33, 2008
50. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA: Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest 119: 1438-1449, 2009
51. Kalluri R: EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119: 1417-1419, 2009
52. Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C: Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 11: 123-151, 2008
53. Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009
54. Yu MA, Shin KS, Kim JH, Kim YI, Chung SS, Park SH, Kim YL, Kang DH: HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol 20: 567-581, 2009
55. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003
56. Zeisberg M, Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429-1437, 2009
57. Cho HJ, Baek KE, Saika S, Jeong MJ, Yoo J: Snail is required for transforming growth factor-beta-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway. Biochem Biophys Res Commun 353: 337-343, 2007
58. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A: The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: A comparison with Snail and E47 repressors. J Cell Sci 116: 499-511, 2003
59. Yang MH, Wu KJ: TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development. Cell Cycle 7: 2090-2096, 2008
60. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428, 2007
61. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A: Targeted disruption of TGF-beta1/ Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 112: 1486-1494, 2003
62. Banh A, Deschamps PA, Gauldie J, Overbeek PA, Sivak JG, West-Mays JA: Lens-specific expression of TGF-beta induces anterior subcapsular cataract formation in the absence of Smad3. Invest Ophthalmol Vis Sci 47: 3450-3460, 2006
63. Aguilera A, Aroeira LS, Ramirez-Huesca M, Perez-Lozano ML, Cirugeda A, Bajo MA, Del Peso G, Valenzuela-Fernandez A, Sanchez- Tomero JA, Lopez-Cabrera M, Selgas R: Effects of rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells. Int J Artif Organs 28: 164-169, 2005
64. Hemers E, Duval C, McCaig C, Handley M, Dockray GJ, Varro A: Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: Implications for epithelial- mesenchymal signaling. Cancer Res 65: 7363-7369, 2005
65. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002 (Pubitemid 37328786)
66. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH: Matrix metalloproteinase 2 and basement membrane integrity: A unifying mechanism for progressive renal injury. FASEB J 20: 1898-1900, 2006
67. Ro Y, Hamada C, Inaba M, Kaneko K, Tomino Y: Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 22: 2838-2848, 2007
68. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG: Encapsulating peritoneal sclerosis: Definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 20[Suppl 4]: S43-S55, 2000
69. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J: Gene transfer of transforming growth factor-beta1 to the rat peritoneum: Effects on membrane function. J Am Soc Nephrol 12: 2029-2039, 2001
70. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, Harada T, Ozono Y, Koji T, Kohno S: TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 66: 1677-1685, 2004
71. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P, Miyata T, Lameire N, Devuyst O: Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 12: 2146-2157, 2001
72. Ha H, Lee HB: Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int 20[Suppl 2]: S15-S18, 2000
73. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH: Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 14: 2109-2118, 2003
74. Margetts PJ, Kolb M, Yu L, Hoff CM, Holmes CJ, Anthony DC, Gauldie J: Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 160: 2285-2294, 2002
75. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, Ritz E, Bierhaus A, Nawroth PP, Zeier M: Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 17: 199-207, 2006
76. Okada H, Inoue T, Kanno Y, Kobayashi T, Watanabe Y, Ban S, Neilson EG, Suzuki H: Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney Int 64: 1722-1732, 2003
77. Kawanishi H, Moriishi M: Encapsulating peritoneal sclerosis: Prevention and treatment. Perit Dial Int 27[Suppl 2]: S289-S292, 2007
78. Sawada T, Ishii Y, Nakajima I, Fuchinoue S, Kubota K, Teraoka S: An experimental model of encapsulating peritoneal sclerosis. Perit Dial Int 29[Suppl 2]: S49-S50, 2009
79. Liu L, Shi CX, Ghayur A, Zhang C, Su JY, Hoff CM, Margetts PJ: Prolonged peritoneal gene expression using a helper-dependent adenovirus. Perit Dial Int 29: 508-516, 2009